NCT07267117 (VALVE-COMPASS) is a clinical trial in Heart Valve Disease, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT07267117?

NCT07267117 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What condition does NCT07267117 study?

NCT07267117 studies Heart Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Valve Disease, Mitral Valve Stenosis, Aortic Valve Disease, Aortic Valve Stenosis, Tricuspid Valve Disease, Tricuspid Valve Regurgitation, Aortic Valve Regurgitation, Pulmonary Valve Disease, Transcatheter Valve Replacement, Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Pulmonary Valve Replacement (TPVR), Transcatheter Edge-to-edge Repair.

Is NCT07267117 still recruiting?

NCT07267117 is currently recruiting now. Last updated 5 December 2025.

Last reviewed 2025-12-05 · How we verify

NCT07267117: VALVE-COMPASS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease

Recruiting now Last updated 5 December 2025

What this trial tests

trial in Heart Valve Disease in 10,000 participants. Currently enrolling.

Timeline

1 June 2025

Primary endpoint
31 December 2027

31 May 2030

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	10,000
Start date	1 June 2025
Primary completion	31 December 2027
Estimated completion	31 May 2030
Sites	15 locations across China

Conditions studied

Heart Valve Disease — all drugs for Heart Valve Disease →
Mitral Valve (MV) Regurgitation — all drugs for Mitral Valve (MV) Regurgitation →
Mitral Valve Disease — all drugs for Mitral Valve Disease →
Mitral Valve Stenosis — all drugs for Mitral Valve Stenosis →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

18 and older, any sex, with Heart Valve Disease or Mitral Valve (MV) Regurgitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate and predict the progression of moderate cardiac valve stenosis and regurgitation using clinical, biological, echocardiographic, computed tomography (CT), and magnetic resonance imaging (MRI) data. Additionally, the study aims to analyze the potential impact of device-based interventions, pharmacological therapy, and lifestyle modifications on disease progression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Heart Valve Disease

Currently open trials in the same condition.

NCT06581471 — The TRICURE EU Pivotal Study · NA · recruiting
NCT06027788 — CTSN Embolic Protection Trial · NA · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07267117 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 5 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07267117.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing